How RAGE turns in rage

Verweij, C. L.

doi:10.1038/sj.gene.6363865

Cited by 7 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RAGE belongs to the large immunoglobulin superfamily, and its gene is located in the class III major histocompatibility complex (MHC) region on chromosome 6 [ 96 ]. The presence of the RAGE gene within this complex suggests a critical role of RAGE in inflammation [ 97 ].…”

Section: The Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer

Taneja

Vetter

Leclerc

2021

IJMS

View full text Add to dashboard Cite

Hypoxia is characterized by an inadequate supply of oxygen to tissues, and hypoxic regions are commonly found in solid tumors. The cellular response to hypoxic conditions is mediated through the activation of hypoxia-inducible factors (HIFs) that control the expression of a large number of target genes. Recent studies have shown that the receptor for advanced glycation end products (RAGE) participates in hypoxia-dependent cellular adaptation. We review recent evidence on the role of RAGE signaling in tumor biology under hypoxic conditions.

show abstract

Section: The Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer

Taneja

Vetter

Leclerc

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…RAGE is a single transmembrane domain multi-ligand cell surface receptor belonging to the immunoglobulin (Ig) superfamily and is encoded in the class III Major Histocompatibility Complex (MHC) at position 6p21.3 [86][87][88][89]. This chromosomal region contains multiple genes involved in inflammatory and immune disorders, suggesting that RAGE plays a role in inflammation as well [90].…”

Section: Rage Structure and Isoformsmentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract